Genmab stock gains support as HC Wainwright reiterates buy rating and $40 target

Published on 09/14/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock is backed by a reiterated Buy rating and a $40 price target from H.C. Wainwright as of September 14, 2026, following stronger than expected Q2 2026 earnings. The biotech group also raised its full-year 2026 revenue and earnings guidance, reinforcing the upbeat analyst view.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab A/S stock (ISIN DK0010272202) is drawing renewed analyst support after H.C. Wainwright reiterated its Buy rating and a $40 price target on September 14, 2026, with the shares trading around USD 32.47 on Nasdaq as of that date, implying upside of roughly 23 percent against the prior close.

Analyst reiteration underpins Genmab stock

According to Investing.com on September 14, 2026, H.C. Wainwright confirmed its Buy recommendation on Genmab A/S (ticker GMAB) and maintained a $40 price target following the company’s second quarter 2026 results.

The same report notes that Genmab delivered net income of USD 4.91 per diluted share in Q2 2026, beating H.C. Wainwright’s previous forecast of USD 4.18 per diluted share by USD 0.73, a positive surprise of about 17.5 percent in earnings per share for the quarter, which is a key driver behind the reiterated rating.Investing.com Brasil

Stronger Q2 2026 figures and higher guidance

As Investing.com France reports, the Q2 2026 earnings beat has prompted H.C. Wainwright to raise its estimate for Genmab’s full-year 2026 net income to USD 14.84 per diluted share, up from an earlier forecast of USD 12.10, which represents an increase of about 22.6 percent in expected annual earnings per share.

The same coverage highlights that Genmab increased its full-year 2026 revenue guidance to a range between DKK 4.3 billion and DKK 4.5 billion following the second quarter, compared with a previously lower outlook, signaling mid to high single-digit percentage upside versus the prior guidance corridor.Investing.com Deutschland

According to Investing.com Brasil, Genmab ended Q2 2026 with about USD 1.5 billion in cash, cash equivalents and marketable securities, providing substantial financial flexibility to support ongoing development of its oncology and immunology pipeline while weathering sector volatility.

Broader analyst consensus and valuation backdrop

An overview from MarketBeat dated September 14, 2026 shows that one analyst currently rates Genmab stock Strong Buy, nine rate it Buy and three rate it Hold, resulting in an overall Moderate Buy consensus with an average target price of USD 39.50, only slightly below H.C. Wainwright’s USD 40 objective.

In addition, valuation metrics from GuruFocus on September 14, 2026 indicate a GF Value of USD 35.80 for Genmab compared with a market price of USD 32.47, suggesting that the shares are approximately 9.3 percent undervalued relative to this fundamental-based fair value estimate.

For investors, the combination of a Q2 2026 earnings beat, higher full-year guidance and a supportive analyst consensus underscores that execution on Genmab’s drug portfolio remains the central driver of the investment story, even as biotech valuations can be sensitive to trial outcomes and regulatory decisions.

Stock level and upcoming checkpoints

Per recent Nasdaq quotes referenced by MarketBeat on September 14, 2026, Genmab stock opened around USD 32.47 on Nasdaq under the ticker GMAB, with H.C. Wainwright’s USD 40 target implying roughly 23 percent potential upside from that price if its scenario for full-year 2026 earnings and revenue materializes.

While the latest analyst action on September 14, 2026 is the primary near-term catalyst, investors will next focus on the company’s forthcoming quarterly report for Q3 2026, which is expected later in the year and will show whether Genmab can maintain the raised revenue range of DKK 4.3 billion to DKK 4.5 billion and deliver net income close to the upgraded USD 14.84 per diluted share forecast.

Genmab stock price and key data

As of September 14, 2026, Genmab stock is trading on Nasdaq in USD with the latest reference price around USD 32.47, compared to a consensus target near USD 39.50 and H.C. Wainwright’s USD 40 target, positioning the shares meaningfully below the average analyst expectations but supported by stronger Q2 2026 results and raised guidance.